Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29–84%) and the median overall survival time was 9.5 months (r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nehls, O, Klump, B, Arkenau, H T, Hass, H G, Greschniok, A, Gregor, M, Porschen, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364257/
https://www.ncbi.nlm.nih.gov/pubmed/12232749
http://dx.doi.org/10.1038/sj.bjc.6600543
_version_ 1782153909653995520
author Nehls, O
Klump, B
Arkenau, H T
Hass, H G
Greschniok, A
Gregor, M
Porschen, R
author_facet Nehls, O
Klump, B
Arkenau, H T
Hass, H G
Greschniok, A
Gregor, M
Porschen, R
author_sort Nehls, O
collection PubMed
description We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29–84%) and the median overall survival time was 9.5 months (range 0.9–26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary. British Journal of Cancer (2002) 87, 702–704. doi:10.1038/sj.bjc.6600543 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2364257
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23642572009-09-10 Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial Nehls, O Klump, B Arkenau, H T Hass, H G Greschniok, A Gregor, M Porschen, R Br J Cancer Clinical We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29–84%) and the median overall survival time was 9.5 months (range 0.9–26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary. British Journal of Cancer (2002) 87, 702–704. doi:10.1038/sj.bjc.6600543 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-09-23 2002-09-23 /pmc/articles/PMC2364257/ /pubmed/12232749 http://dx.doi.org/10.1038/sj.bjc.6600543 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Nehls, O
Klump, B
Arkenau, H T
Hass, H G
Greschniok, A
Gregor, M
Porschen, R
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
title Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
title_full Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
title_fullStr Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
title_full_unstemmed Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
title_short Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
title_sort oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase ii trial
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364257/
https://www.ncbi.nlm.nih.gov/pubmed/12232749
http://dx.doi.org/10.1038/sj.bjc.6600543
work_keys_str_mv AT nehlso oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial
AT klumpb oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial
AT arkenauht oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial
AT hasshg oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial
AT greschnioka oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial
AT gregorm oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial
AT porschenr oxaliplatinfluorouracilandleucovorinforadvancedbiliarysystemadenocarcinomasaprospectivephaseiitrial

Ejemplares similares